CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several years. Both technologies are experiencing exponential growth. While CAR T-cell therapy holds great promise in the fight against cancer, significant hurdles remain preventing realization of its full potential. Several innovative approaches are under investigation to overcome these hurdles. The present article provides a peek into this area of innovation by focusing on the invention described in a recently published patent application, WO/2018/115887, relating to novel CAR T-cells engineered using CRISPR.
The post CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsenal appeared first on IPWatchdog.com | Patents & Patent Law.
Patent
- Enablement
- Fee Shifting
- Litigation
- CAFC Nixes District Court Claim Construction in Win for Firearms Patent Owner
- Tips for Litigating Multiple Simultaneous Patent Infringement Investigations at the ITC
- Other Barks & Bites for Friday, January 14: Property Rights Groups Oppose SEP Draft Policy Statement, PTAB POP Issues Ruling on Wire Transfer of IPR Filing Fee, and SCOTUS Denies Appeal in Breach of Royalty Agreement Case
- Senate Judiciary Committee Sends Vidal and Stark Nominations to Senate Floor
- SCOTUS, Vaccine Mandates and Patent Law: God Help Us
Recent Posts
- CAFC Nixes District Court Claim Construction in Win for Firearms Patent Owner
- Tips for Litigating Multiple Simultaneous Patent Infringement Investigations at the ITC
- Other Barks & Bites for Friday, January 14: Property Rights Groups Oppose SEP Draft Policy Statement, PTAB POP Issues Ruling on Wire Transfer of IPR Filing Fee, and SCOTUS Denies Appeal in Breach of Royalty Agreement Case
- Senate Judiciary Committee Sends Vidal and Stark Nominations to Senate Floor
- SCOTUS, Vaccine Mandates and Patent Law: God Help Us